Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

ContentsSummarized findings and recommendationsThe opportunity• Diabetes is a major and underestimated source of medical costs and lost productivity• Diabetes care in The Netherlands has reached a high level of quality, but there is still opportunity for further improvement• Further improving health of patients may lead to EUR 1.5-2 B of economic benefits in 2020The road• Refine economic incentives to encourage integrated care and quality improvement• Engage employers, UWV and participative care in diabetes care• Engage the patient’s social network to support self management• Introduce conditional market access models for new therapies and medication to assess behavioural impactAppendix: list of sources26
Diabetes care clearly improved in the Netherlands – Values froma selected group of care providersDiabetes care clearly improved in the Netherlands – Values from a7.5%HbA1c values (target value 7% - 53 mmol/mol)HbA1c < 7% / 53 mmol/mol% of patientsILLUSTRATIVE7.1%66.5%69.0%6.7%6.8%60.6%63.0%NA19962000-20072008201019962003200420082010Systolic blood pressuremmHgCholesterol levelmmol/l1556.01455.11381384.54.719962000-20072008201019962000-20072008 2010Note: 1996 data based on 5 networks of GP’s; 2000-2007 data based on all publications from GP’s; 2003 and 2004 hbA1c values < 7% based on study with 7,893 patients spread of NL; 2008 data based on studywith 14,156 patients from 8 networks and cholesterol voor level from met DiabetesZorgBeter diabetes mellitus type networks; 2 in de 2010 1e lijn, data Interview based on Prof. 52,630 G.E.H.M patients Rutten, in 6 Julius networks Center, Booz & Company analysisSource: Diabeteszorggroepen en de keten-DBC, Zorg voor patienten met diabetes mellitus type 2 in de 1e lijn, Interview Prof. G.E.H.M Rutten, Julius Center, Booz & Company analysisBooz & Company 14 November 2011Prepared for Novo Nordisk2027
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27: Increase in lost productivity is dr
Page 31 and 32: Better compliance can be stimulated
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 66: Booz & Company is a global manageme

Diabetes Care in The Netherlands: - Novo Nordisk

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?